Loading organizations...
§ Private Profile · 1 Pepparedsleden, Moelndal, Vaestra Goetaland 43183, SE
Biotech company developing single-molecule microscopy biosensors for label-free drug discovery, focused on membrane proteins.
Key people at In Singulo Solutions AB.
In Singulo Solutions AB, founded October 2017 by Chalmers Professor Fredrik Höök and based in Mölndal, Sweden, develops single-molecule microscopy-based biosensors. Its patent-pending technology, from a Chalmers University of Technology and AstraZeneca five-year collaboration, provides label-free analysis of drug interactions with membrane proteins. This overcomes current biophysics limitations for drug discovery, enabling faster, more precise identification of new drugs. It sells biosensor instruments and consumables (microscope, software, unique sensor plates) to biotech and pharmaceutical companies targeting membrane proteins. It has raised approximately $410K-$440K (SEK 4M) in seed funding from investors including Chalmers Ventures and Swedish business angels. Its business model centers on seed-stage biotech funded by venture capital and grants, sells biosensor instruments and consumables to pharmaceutical companies.
Key people at In Singulo Solutions AB.
# In Singulo Solutions AB: High-Level Overview
In Singulo Solutions AB is a Swedish life science company that develops label-free biosensing technology for drug discovery, diagnostics, and quality control.[1] The company provides a proprietary biosensing platform that enables pharmaceutical researchers to study membrane proteins in their native state, delivering faster drug development cycles with improved precision and reduced costs.[5] Rather than modifying target proteins to fit existing assay methods, In Singulo's technology adapts to the protein itself, preserving biological relevance while achieving single-molecule detection sensitivity.[1]
The company serves pharmaceutical companies and research institutions developing drugs targeting membrane proteins—a critical but historically challenging class of drug targets. By enabling researchers to identify, verify, and release new drugs to market more quickly and with greater precision, In Singulo addresses a fundamental bottleneck in drug discovery where current biosensing methods often compromise data quality or require extensive sample modification.[3]
# Origin Story
In Singulo Solutions AB was founded in October 2017 following a five-year collaboration between Chalmers University of Technology and AstraZeneca, two institutions exploring how to overcome biophysics challenges in drug discovery using single-molecule microscopy.[5] The company was founded by Fredrik Höök, emerging directly from this academic-industry partnership that identified a genuine market need.[3]
The origin story reflects a classic academic spinout model: researchers at Chalmers and scientists at AstraZeneca recognized that existing biosensing methods were inadequate for studying membrane proteins without compromising data quality or requiring prohibitive reagent consumption. This five-year exploration phase validated both the technical feasibility and commercial opportunity before formal incorporation, giving the company a strong foundation and early credibility within the pharmaceutical industry.[1]
# Core Differentiators
# Role in the Broader Life Sciences Landscape
In Singulo operates at the intersection of two powerful trends: the growing recognition that membrane proteins represent underexploited drug targets and the increasing demand for higher-fidelity, faster drug discovery tools. Membrane proteins regulate critical biological processes and are implicated in numerous diseases, yet they remain difficult to study because they require native cellular environments to function properly—a constraint that existing biosensing methods struggle to accommodate.
The company's timing is advantageous as pharmaceutical companies face mounting pressure to accelerate drug development cycles while reducing costs. By enabling researchers to work with proteins in their native state and detect single-molecule interactions, In Singulo removes a technical bottleneck that has historically forced researchers to choose between biological relevance and assay convenience. This positions the company to influence how the entire drug discovery industry approaches membrane protein validation, potentially shifting the standard from label-based to label-free biosensing for this critical application.[5]
# Quick Take & Future Outlook
In Singulo Solutions represents a classic deep-tech opportunity: a company solving a specific, well-defined technical problem for a large, well-funded customer base (pharmaceutical R&D). The company's origins in a genuine academic-industry collaboration, combined with its patent-protected technology and early validation through Chalmers Ventures and business angel investment, suggest a credible path to scaling.[3][5]
The company's future likely hinges on expanding adoption beyond early adopter pharmaceutical companies and demonstrating that the platform can address an expanding range of membrane protein targets. As drug discovery increasingly focuses on previously "undruggable" targets—many of which are membrane proteins—In Singulo's technology could become foundational infrastructure rather than a specialized tool. The broader trend toward precision medicine and personalized therapeutics also creates tailwinds, as higher-fidelity biosensing data becomes increasingly valuable for patient stratification and biomarker discovery.
